Who Is Unsuitable For Using Weight-loss Peptides?

Feb 10, 2026

Palik žinutę

The main groups unsuitable for using weight-loss peptides include: individuals with medullary thyroid carcinoma or a related family history; pregnant and lactating women; individuals with severe renal insufficiency; individuals with a history of acute pancreatitis; individuals allergic to any of the drug's components; and non-obese individuals who do not meet the BMI criteria for medication.

Your concern about who is unsuitable for using weight-loss peptides demonstrates your strong emphasis on safety and suitability when considering weight-loss programs, a commendable rational approach. While weight-loss peptides have significant effects, they are prescription drugs and must be used only after a rigorous health assessment. The following are specific contraindications and groups requiring caution:

 

Patients with thyroid-related diseases


Contraindicated in individuals with multiple endocrine neoplasia type 2 (MEN2);

Reason: GLP-1 receptor agonists may stimulate thyroid C-cell proliferation, increasing the risk of tumors.

 

This medication may affect fetal/infant development through the placenta or breast milk; women planning pregnancy should discontinue use at least 2 months in advance and consult a doctor.

 

<30 mL/min/1.73m²; as the drug is primarily metabolized by the kidneys, it may increase the burden on the kidneys.

 

Use may induce a recurrence of pancreatitis; those with a history of acute attacks within the past six months should especially avoid use.

Contraindicated in patients with a history of allergic reactions such as rash, itching, or difficulty breathing; inform your doctor of any allergy history before use.

 

Minors under 18 years of age:

The body is not fully developed, and the drug may affect the normal development of the metabolic system.